RhumbLine Advisers’s ADC Therapeutics ADCT Stock Holding History

RhumbLine Advisers’s Portfolio ADCT Stock Details ADCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$148K	Buy	120,941 +3,577	+3%	+$4.18K	﹤0.01%	3393
2026 Q2	$126K	Buy	117,364 +13,313	+13%	+$38.8K	﹤0.01%	3452
2026 Q1	$390K	Buy	104,051 +13,368	+15%	+$52.7K	﹤0.01%	2758
2025 Q4	$320K	Sell	90,683 -9,791	-10%	-$39.7K	﹤0.01%	2934
2025 Q3	$402K	Sell	100,474 -2,134	-2%	-$6.73K	﹤0.01%	2837
2025 Q2	$275K	Sell	102,608 -9,021	-8%	-$19K	﹤0.01%	3047
2025 Q1	$157K	Buy	111,629 +1,592	+1%	+$2.7K	﹤0.01%	3223
2024 Q4	$219K	Buy	110,037 +14,848	+16%	+$38.9K	﹤0.01%	3147
2024 Q3	$300K	Buy	95,189 +9,212	+11%	+$29.1K	﹤0.01%	3024
2024 Q2	$272K	Buy	+85,977	New	+$342K	﹤0.01%	3059

Other funds holding ADCT

ACM

AIGH Capital Management Baltimore, Maryland $992M AUM 516.32% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Sanibel Captiva Trust Company Sanibel, Florida $4.04B AUM 26.09% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

RhumbLine Advisers's ADCT Position: Q3 2026 in Review

RhumbLine Advisers increased its ADC Therapeutics (ADCT) stake by 3% in Q3 2026, buying an estimated $4.18K and bringing the position to 120,941 shares worth $148K. The position accounts for ﹤0.01% of the portfolio, ranked #3393.

RhumbLine Advisers first reported a position in ADCT in Q2 2024 and has held it in 10 quarters since. The position peaked at $402K in Q3 2025. 47 funds tracked by Wall St. Rank hold ADCT as of Q3 2026.

RhumbLine Advisers held 120,941 shares of ADC Therapeutics worth $148K as of Q3 2026.
RhumbLine Advisers bought 3,577 ADC Therapeutics shares in Q3 2026, an estimated $4.18K.
ADC Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q3 2026, its #3393 holding.
RhumbLine Advisers first reported a position in ADC Therapeutics in Q2 2024 and has held it in 10 quarters since.
RhumbLine Advisers's ADC Therapeutics position peaked at $402K in Q3 2025.
47 funds tracked by Wall St. Rank held ADC Therapeutics as of Q3 2026.

Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.